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ABSTRACT
Background: Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection increases the 
progression of liver fibrosis to advanced liver disease and death. The aim of this study is to determine whether 
decreased of liver fibrosis occur in HCV/HIV coinfection patients after therapy with Sofosbuvir/Daclatasvir.
Method: This study used a quasi-experimental study design without a control group. The study subjects were 
HCV/HIV coinfection patients who received Sofosbuvir/Daclatasvir therapy in the Gastroentero-hepatology 
Clinic of Dr. Hasan Sadikin Hospital. In this study measurement of liver fibrosis was carried out by using AST to 
platelet ratio index (APRI) and fibrosis-4 index (FIB-4) before therapy and when sustained virological response 
at 24 weeks (SVR-24) was achieved.
Results: The study involved 29 subjects. Most of the research subjects were men, with an average age of 
40.38 years (SD 3.48). From the results of this study, we found a decrease in APRI scores and FIB-4 index when 
HCV/HIV coinfection patients, that were treated with Sofosbuvir/Daclatasvir, achieved SVR 24. The median of 
APRI scores before therapy and after SVR-24 was decreased from 0.41 to 0.28 (95% CI: 0.01 - 0.23; p = 0,01) 
and the median of FIB-4 Index before therapy and after the SVR 24 was decreased from 0.94 to 0.81 (95% CI: 
-0, 04 - 0.35; p = 0.28). 
 Conclusion: This study concluded that therapy using Sofosbuvir/Daclatasvir in HCV/HIV coinfected patients 
has very good effectiveness and can reduce liver fibrosis.
Keywords: HCV/HIV coinfection, liver fibrosis, Sofosbuvir/Daclatasvir
ABSTRAK
Latar belakang: Koinfeksi Hepatitis C Virus (HCV)/ Human Immunodeficiency Virus (HIV) meningkatkan 
progresifitas fibrosis hati menjadi penyakit hati lanjut dan kematian. Penelitian ini bertujuan untuk mengetahui 
apakah terjadi penurunan fibrosis hati pada pasien koinfeksi HCV/HIV setelah diberikan terapi dengan 
Sofosbuvir/Daclatasvir.
Metode: Penelitian ini menggunakan rancangan penelitian kuasi eksperimen tanpa grup kontrol. Subjek 
penelitian adalah pasien koinfeksi HCV/HIV yang mendapatkan terapi Sofosbuvir/Daclatasvir di Unit Rawat 
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Jalan Poli Gastroentero-hepatologi Rumah Sakit Dr. Hasan Sadikin. Pada subjek penelitian dilakukan pengukuran 
fibrosis hati menggunakan Skor AST to platelet ratio index (APRI) dan indeks fibrosis-4 (FIB-4) sebelum terapi 
dan saat SVR-24.
Hasil: Jumlah subjek penelitian sebanyak 29 orang. Sebagian besar subjek penelitian adalah laki-laki, dengan 
rerata usia 40,38 tahun (SD 3,48). Angka keberhasilan Sofosbuvir/Daclatasvir mencapai sustained virological 
response at 24 weeks (SVR-24) pada penelitian ini mencapai 97%. Dari hasil penelitian ini didapatkan penurunan 
skor APRI dan Indeks FIB-4 saat pasien koinfeksi HCV/HIV yang diterapi Sofosbuvir/Daclatasvir mencapai 
SVR 24. Terjadi penurunan skor APRI sebelum terapi dan setelah SVR- 24 dari 0,41 menjadi 0,28, perubahan 
sebesar 0,13 (95% CI: 0,01 – 0,23) dan penurunan Indeks FIB-4 sebelum terapi dan setelah SVR 24 dari 0,94 
menjadi 0,81, perubahan sebesar 0,13 (95% CI: -0,04 – 0,35). 
Simpulan: Penelitian ini menyimpulkan bahwa terapi dengan menggunakan Sofosbuvir/Daclatasvir pada 
pasien koinfeksi HCV/HIV memiliki efektivitas yang sangat baik dan dapat menurunkan fibrosis hati.
Kata kunci: Koinfeksi HCV/HIV, fibrosis hati, Sofosbuvir/Daclatasvir
is associated with HCV infection. Additionally, DAAs 
is proven to be safe to be used in patients with HCV 
monoinfection or HCV/HIV coinfection.2,3,14 In this 
study, we will evaluate the reduction of liver fibrosis 
after treatment using DAAs in HCV/HIV co-infected 
patients.
METHOD
The accessible population was HCV/HIV co-infected 
patients who received Sofosbuvir/Daclatasvir in 
Gastroentero-hepatology Outpatient Polyclinic in Hasan 
Sadikin Hospital in 2017-2018 with inclusion criteria 
of aged more than 18 years, treated with Sofosbuvir/
Daclatasvir and had laboratory data of complete blood 
count, serum aspartate aminotransferase (AST)/serum 
alanine aminotransferase (ALT) before and during 
SVR 24, positive Anti HIV, detected HCV RNA before 
treatment. Exclusion criteria of this study were patients 
who suffered co-infection with hepatitis B virus (HBV), 
those who did not complete treatment according to the 
time planned and failed to achieve SVR-24.
This study was an analytic study with quasi-
experimental design without control group (pretest-
posttest), using primary and secondary data in 
Gastroentero-hepatology Outpatient Polyclinic. Quasi 
experiment is a study to estimate the effect due to an 
intervention without randomization.15 In the single 
group pretest-posttest design, initial measurement 
was performed to all samples, intervention was 
applied to those samples, and a repeat measurement 
was performed in the same set of sample after 
intervention.16 In this study, the sample size was 
determined using mean difference in one paired 
group formula, requiring a sample size of minimum 
22 people. Sample size calculation was based on the 
study performed by Shiffman et al.17,18
INTRODUCTION
The number of patients infected with Hepatitis C 
Virus (HCV) in the world remains quite high. It is 
estimated that approximately 130-170 million people 
are infected by HCV with 10-30% suffering from 
coinfection with human immunodeficiency virus 
(HIV).1,2 This shows that HCV is a global health 
problem and becomes one of the main causes of 
advanced stage liver disease or even death.1-3 HCV/
HIV coinfection can accelerate the occurrence of liver 
fibrosis; hence, liver disease is currently one of the 
main causes of death in patients with HIV infection 
with 30-50% HIV patients died due to terminal stage 
liver disease.3-8 The decreased number of CD4 and 
dysregulation of CD4 function causes the diminishing 
effect of anti fibrosis and increased secretion of 
profibrosis cytokines, which result in the acceleration 
of the occurrence of liver fibrosis in patients with HCV/
HIV coinfection.5,9,10
Liver biopsy is currently the gold standard in 
determining the degree of liver fibrosis, yet liver 
biopsy also has several drawbacks as this procedure 
often causes a range of complications, the cost is quite 
expensive, subjective, and it often causes sampling 
error.11,12 Due to these drawbacks, a non-invasive method 
is developed to evaluate liver fibrosis. The non-invasive 
marker from the blood which was claimed as a substitute 
liver biopsy is AST/platelet ratio (APRI) and FIB-4.12 
In almost two decades, combination of interferon 
(IFN) and ribavirin treatment is the single available 
option for patients with HCV infection with low rate 
of sustained virological response (SVR), particularly in 
patients with HCV/HIV coinfection,1,3 where the SVR 
rate was only about 30%.13 Direct-acting antivirals 
(DAAs) is a new drug, which was proven to increase 
SVR rate and decrease morbidity or mortality rate that 
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Data which would be collected was changes of 
liver fibrosis in patients with HCV/HIV coinfection 
before and after Sofosbuvir/Daclatasvir treatment 
which consisted of primary and secondary data, 
obtained from patients who seek for treatment in 
Gastroentero-hepatology Outpatient Polyclinic Hasan 
Sadikin Hospital. Secondary data being collected was 
liver fibrosis before Sofosbuvir/Daclatasvir treatment, 
which was assessed using APRI score and FIB-4 index, 
in 2017 and 2018. APRI score was calculated using 
the formula as follows: (AST/ upper limit of normal) 
/ trombocyte (109/ L) × 100, meanwhile FIB-4 index 
was calculated using the formula: [age (year) × AST 
(U/L)] /[ PLT (109/L) × ALT (U/L) 1/2]. The treatment 
duration with Sofosbuvir/Daclatasvir was based on 
the APRI score; if the value was < 1, treatment would 
be administered for 12 weeks; if the value was ≥ 1, 
treatment would be administed for 24 weeks. Liver 
fibrosis, which had been quantified using APRI score 
and FIB-4 index, was re-assessed at 24 weeks after 
treatment completion. 
Statistical analysis would be selected according to 
the objective of the study and the proposed hypothesis. 
Before univariate analysis was performed, normality test 
of numerical data was conducted using Shapiro Wilk test 
for data less than 50 people; hence it was known that 
data was normally distributed or not. If the p value is > 
0.05, the data is normally distributed, but if p value is ≤ 
0,05, then the data is not normally distributed. 
Univariate analysis was intended to illustrate the 
characteristics of study subjects which included age, 
sex, complete blood count, AST, ALT, HCV RNA, liver 
fibrosis calculation with APRI score and FIB-4 index 
before treatment. Description of basic characteristics 
were presented in sum and percentage for categorical 
data, while for numerical data it depends on the 
data distribution. If the data is normally distributed, 
univariate analysis is stated in mean and standard 
deviation, but if the sample is not normally distribiyed, 
then it is stated in median with the range.19
Bivariate analysis to assess the change of liver 
fibrosis in HCV/HIV coinfected population between 
before and after Sofosbuvir/Daclatasvir treatment 
was performed using parametric method, particularly 
dependent t test, if data is normally distributed, if the 
data is not normally distributed, the analysis will be 
performed using non-parametric method, the Wilcoxon 
sign Rank test. Data analysis was performed using 
statistical product and service solution (SPSS) software 
for Windows version 22.0 with a confidence interval 
of 95%.
RESULTS
This study was performed in Gastroentero-
Hepatology Outpatient Clinic of Dr. Hasan Sadikin 
Hospital, Bandung in the year 2017-2018. Study 
subjects were patients with HCV/HIV coinfection 
who received Sofosbuvir/Daclatasvir and fulfilled the 
inclusion and exclusion criteria. 
      Bivariate analysis to assess the change of liver fibrosis in HCV/HIV coinfected population 
between before and after Sofosbuvir/Daclatasvir treatment was performed using parametric 
method, particularly dependent t test, if data is normally distributed, if the data is not normally 
distributed, the analysis will be performed using non-parametric method, the Wilcoxon sign Rank 
test. Data analysis was performed using Statistical Product and Service Solution (SPSS) software 
for Windows version 22.0 with a confidence interval of 95%. 
RESULTS 
This study was performed in Gastroentero-Hepatology Outpatient Clinic of dr. Hasan 
Sadikin Hospital, Bandung in the year 2017-2018. Study subjects were patients with HCV/HIV 
coinfection who received Sofosbuvir/Daclatasvir and fulfilled the inclusion and exclusion criteria.  
HCV/HIV coinfected patients who received 
Sofosbuvir/Daclatasvir treatment (n = 65) 
Incomplete laboratory data (n = 35) 
HCV/HIV coinfected patients underwent HCV RNA and laboratory 
examination after 24 weeks End of Treatment (n = 30)
Failed to achieve SVR 24 (n = 1) 
HCV/HIV coinfected patients who fulfilled the 
inclusion and exclusion criteria (n = 29)
There were 65 patients who suffered from HCV/
HIV coinfection who were treated with Sofosbuvir/
Daclatasvir in Gastroentero-hepatology Outpatient 
Clinic of Dr. Hasan Sadikin Hospital and all patients 
have completed the treatment. Two patients were 
excluded from this study because they did not have the 
complete baseline laboratory data, while 33 patients 
were also excluded from the study because they did 
not come in week 24 after completion of treatment for 
the evaluation of HCV-RNA and other laboratory tests. 
From 33 patients who did not come in week 24 after 
completion of treatment, 2 patients did not answer the 
short text message or phonecall, while the other 31 
patients answered the message but unable to attend. 
There were 30 patients with complete laboratory data, 
but 1 patient failed to achive SVR; thus, patients who 
fulfilled the inclusion and exclusion criteria were 29 
patients.
 Characteristics of study subjects based on sex and 
age of HCV/HIV co-infected patients who received 
Sofosbuvir/Daclatasvir in Gastroentero-Hepatolog 
Outpatient Clinic of dr. Hasan Sadikin Hospital can 
be seen in Table 1. 
The median of APRI score before treatment was 
0.41 (0.12-2.13) while the median value of FIB-4 was 
0.94 (0.47-2.55). APRI score < 1 was observed in 25 
people (86.2%), while the score ≥ 1 was observed in 
4 people (13.8%). FIB-4 value of < 1,45 was observed 
in 23 people (79.3%), meanwhile the FIB-4 value of 
≥ 1,45 was observed in 6 people (20,7%). 
Figure 1. Flowchart of the study results
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 A total of 36 patients was excluded from this study. 
The average age of patient being excluded was 39.14 
(SD: 3.34), consisted of 28 male patients (78%) and 8 
female patients (22%). From 36 patients being excluded, 
34 patients had complete laboratory data. The median 
APRI score and FIB-4 index from these patients before 
sofosbuvir/daclatasvir treatment was 0.40 (0.18-4.2) 
and 0.76 (0.3-8.43). APRI score < 1 was observed in 27 
patients (79%) and APRI ≥ 1 was observed in 7 patients 
(21%). FIB-4 < 1,45 was obserbed in 26 patients (76%) 
and FIB-4 ≥ 1,45 was found in 8 patients (24%).
 Bivariate analysis was performed to analyse the 
change of liver fibrosis in HCV/HIV co-infected 
patients before and after Sofosbuvir/Daclatasvir 
treatment using a non-parametric method, the 
Wilcoxon sign rank test, because the data was not 
normally distributed. The difference of APRI score 
and FIB-4 index in HCV/HIV co-infected patients 
before and after Sofosbuvir/Daclatasvir treatment 
in Gastroentero-hepatology Outpatient Clinic of Dr. 
Hasan Sadikin Hospital can be seen in Table 2. 
 In Table 2 it could be seen that there was a 
significant decrease of AST and ALT after sofosbuvir/
daclatasvir treatment. Trombocytes was relatively 
unchanged, while there was a decrease in albumin 
value after sofosbuvir/daclatasvir treatment.
Table 1. Characteristics of study subjects (n = 29)
Variable n (%) Mean (SD) Median  (min-max)
Age (years)
 ≤ 35
 35-45
 ≥ 45
Sex
 Male
 Female
IDU
AST (U/L)
ALT (U/L)
Platelet (103/mm3)
Albumin (g/dl)
HCV RNA
 Positive
 Negative
APRI
 <1 
 1-2
 >2
FIB-4
 <1.45
 1.45-3.25
 > 3.25
3 (10.3)
24 (82.8)
2 (6.9)
22 (75.9)
7 (24.1)
29 (100)
29 (100)
0 (0)
25 (86.2)
2 (6.9)
2 (6.9)
23 (79.3)
6 (20.7)
0
40.38 
(3.478)
243 (65,9)
40.0 (14-172)
41.0 (9-310)
4.31 (3.25-5.07)
2.57 E06 
(<10-1.20E07)
0.41 (0.12-2.13)
0.94 (0.47-2.55)
IDU: injecting drug use, AST: aspartate aminotransferase, ALT: alanine 
aminotransferase, HCV RNA: hepatitis C virus ribonucleic acid, APRI: 
aspartate aminotransferase to platelet ratio index, FIB-4: fibrosis-4
Table 2. The difference of thrombocyte, albumin, AST, and ALT 
values with the use of treatment
Variables Before treatment
During  
SVR 24
p
AST (U/L) 40 (14 – 172) 24 (11 – 55) < 0.001b*
ALT (U/L) 41 (9 – 310) 26 (16 – 69) 0.001b*
Trombocyte (103/mm3) 242 (65) 243.3 (55,4) 0.965a
Albumin (g/dL) 4.32  
(3.25 – 5.07)
4.20  
(3.60 – 5.00)
0.021b*
Notes: Analysis was performed using at-test, bWilcoxon test, *significant 
p < 0.05. AST: aspartate aminotransferase, ALT: alanine aminotransferase, 
SVR: sustained virological response
Table 3. APRI score and FIB-4 index before and after treatment
Variables
Before  
treatment
After  
SVR 24 Difference
p
Median 
(min – max)
Median 
(min – max)
Median  
(95% CI)
APRI  
score
0.41  
(0.12 – 2.13)
0.28  
(0.09 – 0.75)
0.13  
(0/01 – 0.23)
0.001*
FIB-4 i 
ndex
0.94  
(0.47 – 2.55)
0.81  
(0.36 – 1.56)
0.13  
(-0.04 – 0.35)
0.028*
Note: Analysis was performed using Wilcoxon test, *significant p < 0,05. APRI: 
aspartate aminotransferase to platelet ratio index, FIB-4: Fibrosis-4, SVR: 
sustained virologic response
Figure 2. Boxplot changes of APRI score and FIB-4 before and after treatment
From the aforementioned analysis results, it was 
found that there was a decrease in APRI score and FIB-
4 index when HCV/HIV co-infected patients who were 
treated with Sofosbuvir/Daclatasvir achieved SVR 24 
with APRI score before and after therapy from 0.41 
to 0.28. The change was 0.13 (95% CI: 0.01 – 0.23), 
which based on statistical analysis showed significant 
difference. The FIB-4 index before and after treatment 
from 0.94 to 0.81. The change was 0.13 (95% CI: -0.04 
– 0.35), which based on statistical analysis showed 
significant difference. 
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 Before sofosbuvir/daclatasvir treatment, there 
were 25 (86.2%) patients with APRI score < 1.4 
patients (13.8%) with APRI score ≥1. After sofosbuvir/
daclatasvir treatment, all HCV/HIV co-infected 
patients had APRI score < 1. Twenty-three (79.3%) 
patients had FIB 4 index of < 1.45, 6 (20.7%) patients 
had FIB 4 index of ≥ 1.45 before being treated with 
Sofosbuvir/Daclatasvir. Meanwhile, after treatment 
28 patients (96.5%) has FIB 4 index of < 1.45 and 1 
patient (3.5%) had FIB-4 index of ≥ 1.45.
DISCUSSION
In this study, 22 (75.9%) subjects were male. 
The results of this study was in accordance with 
the epidemiologic data of HIV patients in Teratai 
Polyclinic Hasan Sadikin Hospital in 2007 which was 
dominated by male, 68% from 611 HIV patients.20 
HIV cohort study in Asia reported HCV/HIV co-
infected patients were 85% male from 794 HCV/HIV 
coinfected patients being studied.21 A study performed 
by Nunes et al showed HCV/HIV coinfected patients 
was 71% male from 207 patients being studied and 
a study by Sanvisens et al stated 81.5% from 243 
HCV/HIV coinfected patients were male.22,23 Bansal 
stated that male who were infected with HCV often 
developed into liver fibrosis and cirrhosis.9 As stated 
by Rollet-Kurhajec, this was possible due to the 
presence of estrogen hormone in female which inhibit 
the proliferation of stellate cells that has protective 
effect in the liver.7
The mean age of HCV/HIV coinfected patients in 
this study was 40.38 years (SD: 3.478). This result 
was different from the epidemiologic data of young-
aged male HIV patients with IDU history in Teratai 
Polyclinic Hasan Sadikin Hospital year 2007 (median 
age 28 years).20 The majority of the sample in this 
study was existing patients who were included in the 
study in Teratai Polyclinic Hasan Sadikin Hospital in 
2007, with 21 patients (72%) were diagnosed with HIV 
before 2007 and 8 patients (28%) were diagnosed with 
HIV after 2007. Several epidemiologic data showed 
the same results with variable median and age range. A 
study by Sanvisens et al23 found that the median age of 
HCV/HIV coinfected patients was 31 years with an age 
range of 27-35 years, TAHOD cohort study by Chen et 
al reported the age range of study subjects was 40-50 
years, and the study by Kirk et al showed a median age 
of 49 years.6,21 Bansal et al stated that the progression 
of liver fibrosis into cirrhosis was associated with 
advanced age during infection, increased in accordance 
to the duration of HCV infection, and one third of 
patients developed into cirrhosis after 13 years being 
infected with hepatitis virus.9 Dusheiko stated that 
cirrhosis was found in 2% patients who were infected 
with HCV at the age of < 20 years, 6% patients infected 
with HCV at the age of 31-40 years, 37% patients were 
infected with HCV at the age of 41-50 years, and 63% 
patients infected with HCV at the age of > 50 years.24 
Old age might be associated with the shortening of 
hepatocyte telomere that results in the decrease of 
function and regeneration ability of the hepatocyte.25
The success rate of Sofosbuvir/Daclatasvir to 
achieve SVR-24 in HCV/HIV coinfected patients in 
di Gastroentero-hepatologi Clinic of Hasan Sadikin 
Hospital was 97%. This result was similar to that 
of previous study performed by Wyles et al.26 HCV 
RNA examination after treatment in this study was 
performed in week 24 after completion of treatment 
(SVR-24), although based on the National Consensus 
of Hepatitis C Management in Indonesia year 2017 
(Konsensus Nasional Penatalaksanaan Hepatitis C di 
Indonesia tahun 2017) SVR-24 was more appropriate 
for patients receiving interferon therapy; while patients 
who received DAAs therapy can use SVR-12.27 In the 
study by Chen et al there was a conformity between 
SVR-12 and SVR-24. Hence, both modalities could be 
used to determine recovery of HCV patients.28
In this study, there were 4 study subjects who 
suffered from liver cirrhosis. This was shown from the 
calculation of APRI score particularly in 25 (86.2%) 
subjects who had APRI score < 1 and 4 (13.8%) 
subjects who had APRI score ≥1, with a median of 
0.40 with minimum value of 0.12 and a maximum 
value of 2.13. Majority study subjects experienced 
mild liver fibrosis where from the calculation of FIB-
4 index, 23 subjects (79.3%) had mild liver fibrosis 
with a score of < 1.45, 6 (20.7%) subjects had severe 
liver fibrosis with FIB-4 index value of ≥1.45, with a 
median FIB-4 index of 0.81 with a minimum value 
of 0.36 and a maximum value of 1.56. In the study 
conducted by Widiayati et al in Teratai Polyclinic Dr. 
Hasan Sadikin Hospital, the results of the study were 
not of much difference. Most study subjects (80.5%) 
had mild liver fibrosis, 14.4% had severe liver fibrosis 
and 5.1% had cirrhosis.12 In another study performed 
by Salmon et al different results were observed. From 
53 HCV/HIV coinfected study subjects, 18 (34%) 
patients suffered from cirrhosis with a median FIB-4 
index value of 2.01 (1.32-2.59).29 A study conducted 
in Egypt by Mehrez et al in HCV/HIV coinfected 
patients found a quite high mean value of FIB-4 of 
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1.97 with a standard deviation of 1.38.12 Labarga et 
al who perfomed a Fibroscan examination in HCV/
HIV coinfected patients, found that 33.3% from 138 
sample suffered from severe liver fibrosis (F3-F4).30 
HCV/HIV coinfection may accelerate the development 
of liver fibrosis. Therefore, until recently liver disease 
is one of the highest mortality causes in HIV infected 
patients with 30-50% HIV patients died due to 
terminal stage liver disease.3-8 The decrease of CD4 
number and dysregulation of CD4 function causes 
the decrease of anti fibrosis effect and an increase of 
profibrosis cytokine secretion which may lead to the 
acceleration of development of liver fibrosis in HCV/
HIV coinfected patients.5,9,10
  In this study, there was a decrease in AST and 
ALT after treatment with Sofosbuvir/daclatasvir, each 
from a median of 40 and 41 to 24 and 26. This result 
was in accordance with previous study performed 
by Khan et al which stated AST and ALT decreased 
significantly in hepatitis C patients who achieved SVR 
after treatment with DAAs.31
Thrombocyte values in this study did not differ 
significantly after Sofosbuvir/Daclatasvir therapy. 
This result was slightly different from previous 
study by Kwong et al which stated that SVR in HCV 
monoinfected patient might increase platelet value 
significantly. In this study, platelet values did not 
change as the mean thrombocyte before treatment 
was quite high, particularly 243.000/mm3 with a 
standard deviation of 65.900/mm3, while in the study 
of Kwong et al the mean platelet was 172.000/mm3 
with a standard deviation of 56.000/mm3.. In the study 
conducted by Kwong et al, it was stated that the increase 
in thrombocyte values occurred particularly in patient 
with thrombocyte values of less than 150.000/mm3 
before treatment. In patient with cirrhosis or severe 
fibrosis the platelet value was correlated with histologic 
abnormalities of the liver and portal pressure. The 
change in platelet value after patient achieved SVR in 
chronic hepatitis C patient was associated with degree 
of liver fibrosis.32
Albumin is produced by the liver and will decrease 
in the presence of liver cirrhosis. In this study there 
was a decrease in albumin before and after Sofosbuvir/
Daclatasvir treatment from a median of 4.32 before 
treatment to 4.20 after treatment. Results of this study 
were different from those of Kan et al who observed 
the presence of albumin increase in HCV monoinfected 
patients achieving SVR 24 after treatment with 
Daclatasvir/Asunaprevir (DAAs). However, in the 
same study it was also stated that the increase of 
albumin was only observed in patients with albumin 
value of less than 4 g/dL before treatment. In patients 
with albumin levels of more than 4 g/dL, there was no 
significant difference before and after achieving SVR 
24.33 The change of albumin value could be caused 
by the disruption of production causing malnutrition, 
malabsorption or cirrhosis and increase of excretion 
which often happen in nephropathy/enteropathy.34 
In this study, we did not know the nutritional status, 
kidney function or gastrointestinal complaints of the 
participants, as these factors may influence the albumin 
value. 
APRI score decreases after HCV/HIV coinfected 
patients were treated with Sofosbuvir/daclatasvir until 
achieving SVR 24 as shown by a decrease in median 
value before and after therapy from 0,41 to 0,28, a 
change of 0,13 (95% CI: 0,01-0,23). Before treatment 
with Sofosbuvir/Daclatasvir, there was 4 cirrhosis 
patients with APRI score ≥1, but after treatment all 
these 4 patients experienced improvement of liver 
fibrosis, with all subjects had an APRI score of < 1. 
FIB 4 index decreased after HCV/HIV coinfected 
patients were treated with Sofosbuvir/Daclatasvir 
achieving SVR 24 as shown by a decrease in median 
values before and after treatment from 0.94 to 0.81, 
with a change of 0,13 (95% CI: -0,04 – 0,35). Before 
treated with Sofosbuvir/Daclatasvir there were 6 
(20,7%) subjects who had severe liver fibrosis with 
FIB-4 index of ≥1,45, meanwhile after treatment 
with Sofosbuvir/Daclatasvir there were only 1 (3,5%) 
subject with severe liver fibrosis, 5 remaining patients 
experienced liver fibrosis improvement with FIB-4 
value of < 1,45.
The results of this study were in accordance with 
previous studies which stated that Hepatitis C treatment 
that successfully achieves SVR in HCV monoinfected 
patients or HCV/HIV coinfected patients may decrease 
liver fibrosis. A study in Switzerland by Bachofner et al 
reported that SVR might decrease liver fibrosis in HCV 
monoinfected patients, where liver fibrosis before and 
18 months after therapy was calculated using transient 
elastography (TE), APRI score and Fib-4 index. This 
study involved 549 patients, where all patients received 
DAA. Median TE before DAA treatment was 12.65 
kPa (IQR 9.45-19.2 kPa), meanwhile 18 months after 
therapy decreased to 8.55 kPa (IQR 5.93-15.25), with 
p < 0.001. Median FIB-4 index and APRI score also 
decreased significantly from 2.54 (IQR 1.65-4.43) 
and 1.10 (IQR 0.65-2.43) to 1.80 (IQR 1.23-2.84, p < 
0.001) and 0.43 (IQR 0.3-0.79), p < 0.001).35 A study 
by Chekuri et al which involved 100 HCV patients in 
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New York in 2016 stated that liver fibrosis decreased 
after patients achieved SVR 24, with an LS median 
score decreased from 10.40 kPa (IQR: 7.25-18.60) 
before treatment to 7.60 kPa (IQR: 5.60-12.38) when 
SVR 24 with p < 0.01.36 
A study in HCV/HIV coinfected patients by Salmon 
et al in France, from 98 patients who were treated with 
combination of peg-interferon and ribavirin or protease 
inhibitor, 53 (54%) patients achieved SVR. There was 
a decrease in liver fibrosis at least 30% which was 
calculated using TE in patients who achieved SVR, 
which were 51% (95% CI: 39-66). This value was 
higher compared to patients who did not achieve SVR 
which was only 21% (95% CI:11-36). Meanwhile, 
in the second year follow up, 74% (95%CI:61-86) 
patients achieved SVR experienced decrease in liver 
fibrosis as much as 30 % compared to 28% (95% CI: 
17-24) in patients without SVR.37 Meanwhile, the study 
by Mehrez et al in Egypt with a total of study subjects 
of 50 patients reported that treatment with DAAs in 
HCV/HIV coinfected patients might decrease liver 
fibrosis 12 weeks after treatment. APRI score decrease 
up to 66% while the FIB-4 index decreased to 36.8%.12
Before being treated with Sofosbuvir/Daclatasvir, 
there was 4 HCV/HIV coinfected patients who 
experienced cirrhosis, marked by APRI score ≥ 1. 
After sofosbuvir/daclatasvir treatment, all patients 
experienced improvement in liver fibrosis which 
was marked by the decrease of APRI score <1. It 
showed that liver fibrosis in HCV infected patients 
is reversible. A study on the reversibility of liver 
cirrhosis have been studied previously. In a meta-
analysis study which involved 137 HCV patients who 
succeeded in achieving SVR after being treated with 
interferon regiment found regression in liver cirrhosis 
in 51% sample, whereas the longer the duration 
between liver histology sample collections, the liver 
fibrosis decrease was even higher.38 Data regarding 
the reversibility of liver cirrhosis in HCV infected 
patients who were treated with DAAs has not been 
widely studied as currently liver biopsy examination 
is rarely performed in HCV infected patients, while 
liver biopsy is still considered as the gold standard in 
evaluating reversibility of liver cirrhosis.39 Pineda et 
al performed a study to observe the change of liver 
fibrosis using TE in cirrhosis patients caused by HCV. 
There were 49 patients with TE value of >12,5 kPa who 
succeeded to achieve SVR 12 after DAAs treatment. 
In this study, there was a liver cirrhosis reversibility 
in 12 patients (24%).38,39
Reversibility of liver cirrhosis did not occur in 
all cirrhosis patients who achieve SVR. In the study 
performed by Grgurevic et al, it was concluded that 
cirrhosis reversibility only happens in patients with 
compensated cirrhosis. HCV eradication in patients 
with decompensated liver cirrhosis will not stop the 
development of liver fibrosis.38 A study performed 
by Lens et al and Mandrofer et al concluded that 
administration of DAA treatment in patients with 
significant portal hypertension did not succeed to 
decrease portal pressure in majority of patients.38,40 
In patients with decompensated liver cirrhosis which 
was caused by HCV, it would be better if DAAs was 
not only given to decrease liver fibrosis but also can 
be given as antifibrosis drug, although this may need 
further studies.38
This study showed that Sofosbuvir/Daclatasvir 
treatment can decrease liver fibrosis, which was 
calculated using APRI score or even FIB-4 index, 
in HCV/HIV coinfected patients. Evaluation of liver 
fibrosis in HCV infected patients was an important 
factor not only to observe the success of treatment but 
also to determine patient’s prognosis.41,42 The decrease 
in liver fibrosis is very important as it has been proven 
to decrease mortality and liver cancer incidence in 
HCV infected patients.37,41,43
In HCV/HIV coinfected patients, there was an 
increase of hepatocyte apoptosis which cause the 
activation of stellate cell and increase collagen 
expression or inflammation mediator. Successful 
Hepatitis C treatment in HCV/HIV coinfected patients, 
which was marked by the achievement of SVR, may 
cause apoptosis of stellate cells and decrease in liver 
fibrosis.44-46
The limitations of this study include: (1) This 
study did not include data on other factors which 
may influence liver fibrosis such as the use of other 
drugs beside ARV and Sofosbuvir/Daclatasvir, the use 
of alcohol and other disease which may cause liver 
fibrosis such as metabolic syndrome; (2) There was a 
lot of study subjects with incomplete data who needs 
to be excluded, thus may alter the study results; (3) 
This study did not include HCV genotype data, thus 
this study may not be applied in all population of HCV/
HIV coinfected patients.
CONCLUSION
There was an improvement in the degree of liver 
fibrosis which was signified by the decrease of APRI 
score and FIB-4 index in HCV/HIV coinfected patients 
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Daclatasvir treatment.
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